Introduction 63
The impact of bone metastases on cancer patients can be considerable. Complications, 64 reduced mobility, pain and the effects of treatment reduce quality of life significantly. 65
Complications may include pathological fracture, spinal cord compression and 66 hypercalcaemia of malignancy. 67
Bone-targeted pharmacological treatments aim at preventing complications, reducing pain 68 and improving quality of life. To date bisphosphonates have been the main pharmacological 69 treatment option for patients with bone metastases. Currently licensed bisphosphonates 70 include; zoledronic acid (any advanced malignancy involving bone), disodium pamidronate 71 (breast cancer or multiple myeloma), sodium clodronate (breast cancer or multiple myeloma) 72 and ibandronic acid (breast cancer). Bisphosphonates are administered either intravenously 73 (zoledronic acid, pamidronate or ibandronic acid) or orally (clodronate or ibandronic acid) 74
and have been associated with renal toxicity. 1 In the UK, the National Institute of Health and 75
Clinical Excellence (NICE) currently recommends the use of bisphosphonates in all patients 76 with bone metastases secondary to breast cancer, 2 patients with hormone resistant prostate 77 cancer with painful bone metastases despite conventional analgesics 3 or as an option in 78 lung cancer with bone metastases. 4 Patients who are not recommended for 79 bisphosphonates would receive standard best supportive care. 80
Denosumab (Xgeva, Amgen) is a fully human monoclonal antibody, licensed for the 81 prevention of skeletal related events (SRE) in bone metastases from solid tumours. It is 82 administered by sub-cutaneous injection and does not require renal monitoring. 5 
83
The term 'skeletal related event' is a composite endpoint that has evolved over the past 20 84 years for use in clinical trials. Recent trials define SREs as pathological fracture (including 85 asymptomatic vertebral collapse), spinal cord compression or need for radiotherapy or 86 surgery to bone. [6] [7] [8] Other definitions have included hypercalcaemia or change in anti-87 neoplastic therapy. 88
Three pivotal trials have evaluated denosumab compared to zoledronic acid for the 89 prevention of SREs. [6] [7] [8] There are no head-to-head trials of denosumab compared with other 90 bisphosphonates or best supportive care. These comparisons are, nonetheless, important 91 because of the wide variation in practice. Some centres use only zoledronic acid, some use 92 a variety of bisphosphonates, while others do not use bisphosphonates at all (especially in 93 cancer other than breast). Therefore the aim of this review is to evaluate the evidence for 94 denosumab for the treatment of bone metastases in solid tumours and, using a network 95 credible intervals taken from the 2.5% and 97.5% percentiles. Ten thousand MCMC 165 simulations were used in the analysis following a burn-in of 10,000. The same approach 166 was taken for modelling rate ratios in the analysis of time to first and subsequent SREs. 167
For SMR a random effects model was adopted using arm-based data. The data included in 168 the SMR models were mean SMR and standard deviation along with the number of patients. 169
Where standard deviations were not reported, values were imputed by taking the mean of 170 reported SDs from other studies but for the same treatment. The robustness of the 171 imputation was tested by comparing results with those obtained by treating missing data as 172 an uncertain parameter. Posterior distributions for relative treatment effects were estimated 173 from the absolute risks of outcome from the relevant individual treatments. Median 174 estimates and credible intervals were taken from 10,000 MCMC simulations after a burn-in 175 of 10,000. 176
In order to estimate the absolute risk of outcome in the analyses of arm-based data, it was 177 necessary to include an estimate of the baseline risk of the control treatment in the models. 178
Zoledronic acid was treated as the reference treatment in each analysis as it is the treatment 179 common to the largest number of trials and is present in multiple included studies for each 180 NMA. Single-arm meta-analyses of zoledronic acid were conducted to estimate baseline 181 risk from studies included in the NMA that had zoledronic acid as one of its comparators. 182
The data in the time-to-event analyses, however, were trial-based and baseline risk could 183 not be estimated so the absolute effect of the reference treatment was set to zero in these 184
models. 185
The quality of the models was examined by inspecting convergence using Gelman-Rubin-186
Brooks plots, assessing autocorrelation between iterations of the Markov chain and checking 187 whether the MC error was less than 5% of the posterior standard deviation.
Results

190
Literature search 191
Results of the literature search are shown in figure 1. Thirty-eight studies met the inclusion 192 criteria, most of which compared bisphosphonates with placebo. Of these 38 studies, 30 193 were excluded because they were not suitable for network meta-analysis (table 1) 
196 197
Study quality 198
The quality of the studies included in the NMA was high as shown in Pain outcomes for denosumab compared with zoledronic acid in other solid tumours is 239 available in abstract form. 21 Denosumab was found to delay the time to clinically significant 240 pain (more than 2 point increase from baseline on brief pain inventory) compared to 241 zoledronic acid (169 days compared with 143 days HR 0.85, 95% CI: 0.73-0.98). 242
In prostate cancer, pain data have also been published in abstract form. 22 In the subgroup of 243 patients with no/mild pain at baseline, there was no statistically significant difference in the 244 time to moderate/severe in denosumab compared to zoledronic acid (177 days versus 148 245 days; HR 0.89, 95% CI 0.77, 1.04).
Quality of life study results 247
In breast cancer, quality of life data for denosumab have been published in abstract form. 23 
248
The authors report that over the 18 month period an average of 4.1% more (range -0.6% to 249 9.3%) patients treated with denosumab, compared with zoledronic acid, experienced a 250 meaningful improvement in quality of life (5 or more increase in FACT-G score 
Denosumab versus pamidronate 283
The comparison of denosumab versus pamidronate was only possible in breast cancer. For 284 skeletal morbidity rate the result favours denosumab, but there was no significant difference. 285
There was a significant difference in time to first SRE and time to first and subsequent SRE 286 when denosumab was compared with pamidronate (HR 0.73 95%CI 0.56 to 0.94 and rate 287 ratio 0.62 95%CI 0.48 to 0.80, respectively).
Discussion 289 290
Statement of key findings 291
Based on the review of direct evidence and network meta-analysis, denosumab, compared 292 with zoledronic acid or placebo, statistically significantly delays time to first SRE, time to first 293 and subsequent SRE and skeletal morbidity rate. Denosumab appears to be more effective 294 than pamidronate for these outcomes, but the results have mixed statistical significance. 295
Although denosumab has demonstrated its effectiveness in delaying SREs, a lack of 296 published data means that conclusions about pain and quality of life cannot be made. There 297 was no statistically significant difference in overall survival for denosumab compared with 298 zoledronic acid for prostate and breast cancer. However in an ad hoc analysis of the trial 299 including various tumour types, denosumab was found to improve the overall survival in non-300 small cell lung cancer. 301 302
Strengths and limitations 303
There are a number of strengths of this review. A comprehensive and robust search strategy 304 was used. A rigorous inclusion/exclusion criteria was used which only included high quality 305 evidence (RCTs). Undertaking a NMA means that estimates of effectiveness can be made 306 when no direct evidence is available. This was the case for comparing denosumab with 307 placebo and pamidronate. Excluding studies with a different definition of what constitutes an 308 SRE resulted in a smaller but more robust NMA. 309
Although NMA allows indirect estimates to be calculated, they can be subject to potential 310 biases and uncertainties.
25 Network meta-analyses are not randomised comparisons, but 311 rather observational findings across studies and therefore should be interpreted with due 312
caution. The quality of any NMA is only as good as the weakest link in the network. All 313 studies included in this NMA were of good quality (table 4), improving the validity of the NMA 314 results. Some published studies did not report full results, therefore some treatment effects 315 were estimated, for example using the method described by Teirney and colleagues. 15 
316
However when these parameters were treated as uncertain, the impact on the results was 317 negligible. A key limitation was the small number of studies included. This resulted in an 318 unstable model when a random effects model was used for time to first SRE and time to first 319 and subsequent SRE. Therefore a fixed effects model was used, which assumes no 320 variability between studies. 321 322 323
Meaning of the results 324
Our analysis indicates that denosumab is effective in delaying first and first-and-subsequent 325
SREs when compared to zoledronic acid, placebo and pamidronate. NMA analysis results in 326 reduced power and therefore less precision. Non-statistically significant results for skeletal 327 morbidity rate for denosumab compared with pamidronate should not be interpreted as 328 evidence that there is no effect. Only if higher powered NMA were possible could this 329 conclusion be made. 330
The validity of these results relies on, firstly, the SRE outcome and, secondly, the analysis of 331 it. The SRE outcome is useful because it allows for increased power and therefore 332 efficiency. It would be impractical to power trials to detect differences in each component of 333 the SRE outcome, especially with regard to spinal cord compression and need for surgery to 334 bone (as these are rare events). However, the composite outcome is of little use to patients 335 since it incorporates a wide spectrum of clinical events, ranging from asymptomatic 336 pathological fracture (identified during routine on-study skeletal surveys) to paraplegic spinal 337 cord compression. Furthermore, the outcome does not directly measure mobility or bone 338 pain, although it could be argued that the need for radiotherapy is an indirect measure of 339 bone pain. In addition, for many patients, radiotherapy will be a highly effective treatment for 340 bone pain. 341
Using time to event and multiple event analyses (time to first and subsequent SRE) allows 342 smaller differences between treatments to be identified. This may be warranted when 343 comparing active comparators; however, researchers and healthcare staff should ensure 344 that statistically significant differences are clinically meaningful. In addition, the method used 345 in these trials for the multiple event analysis (Andersen-Gill 13 ) has been criticised because it 346 does not differentiate between participants who died and who leave the study for another 347 reason. 26 These issues have been discussed in greater detail elsewhere.
27
348
A key issue is whether the delay in SREs results in a reduction in pain and improvement in 349 quality of life. Ideally, the improved SRE outcomes with denosumab, would be interpreted 350 alongside pain and quality of life data. Unfortunately, the lack of published pain and quality 351 of life data means that this association could not be established. The data published from the 352 three pivotal trials are only available in abstract form and generally only reports subgroups. 353
For breast cancer there was a statistically significant delay to moderate/severe pain in 354 patients with no/mild pain, however in prostate cancer the difference was not statistically 355
significant. 356
Denosumab has the added advantage of being given as a sub-cutaneous injection which 357 does not require renal monitoring. Denosumab could potentially be administered in the 358 community. Zoledronic acid is an intra-venous administration and requires renal monitoring 359 with dose adjustment if renal impairment present. In terms of adverse events, denosumab 360 has lower renal toxicity and does not appear to be associated with acute phase reactions. 361
However, there is a marginally higher incidence of osteonecrosis of the jaw. In addition, 362
there is a higher incidence of hypocalcaemia but this can be easily corrected with 363 appropriate treatment. 364 365
Future research needs 366
In common with most findings for bisphosphonates in advanced cancer, from available 367 evidence denosumab does not appear to affect overall survival. In the Henry 2010 trial, 24 
368
there was a statistically significant improvement in overall survival in the ad hoc analysis for 369 non small cell lung cancer. The reason for this is not clear and it may be a chance finding. 370
Further trials in this subgroup would be needed to establish the validity of this result.. 371
The place for denosumab in treatment pathways is unclear. Much of this will depend on local 372 budgets and on economic evaluations.
28,29 One option may be as a second line agent in 373 patients who suffer an SRE on bisphosphonates. A randomised controlled trial looking at this 374 specific population may be informative. 375
376
Conclusion 377
Denosumab compared with zoledronic acid, placebo and, pamidronate, is effective in 378 delaying time to first SRE and reducing the risk of first and subsequent SRE. However, 379 conclusion about its impact on pain reduction and quality of life cannot be reached because 380 of the lack of published data. 381
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